What one share of Genprex holds
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.
Genprex’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$14.75 |
|---|---|
| Cash and investments | $29.94 |
| Book value | $29.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.00 | −$1,010 | $0.99 | −$785.56 | — | — |
| 2021 | $0.00 | −$840.00 | $1.35 | −$607.96 | — | — |
| 2022 | $0.00 | −$990.15 | $0.00 | −$734.94 | — | — |
| 2023 | $0.00 | −$1,128 | — | — | — | — |
| 2025 | — | −$17.40 | — | — | — | $2.42 |
Common questions about Genprex
How much does one share of Genprex earn?
Over the last 12 months, Genprex lost $14.75 for each share.
Does Genprex pay a dividend?
Genprex didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Genprex’s book value per share?
Genprex’s book value is $29.23 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Genprex have?
Each share of Genprex has $29.94 of cash and investments, as of June 30, 2026.
Has Genprex bought back shares?
Genprex’s share count rose about 5151% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.